Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3
D Kellerman, AR Mospan, J Engels, A Schaberg… - Pulmonary …, 2008 - Elsevier
Among the most promising of the new therapies being developed for the treatment of Cystic
Fibrosis (CF) are those targeted at increasing mucosal hydration on the surface of the
airways. One of these therapies, P2Y2 receptor agonists, bypasses the defective CFTR
chloride channel, and activates an alternative chloride channel. This activation results in an
increase in airway surface epithelial hydration, and through these actions and effects on cilia
beat frequency, increases mucociliary clearance. The pharmacology of P2Y2 agonists has …
Fibrosis (CF) are those targeted at increasing mucosal hydration on the surface of the
airways. One of these therapies, P2Y2 receptor agonists, bypasses the defective CFTR
chloride channel, and activates an alternative chloride channel. This activation results in an
increase in airway surface epithelial hydration, and through these actions and effects on cilia
beat frequency, increases mucociliary clearance. The pharmacology of P2Y2 agonists has …